A pair of neurologists from the University of California, Irvine, provided commentary on the ways to help young investigators find their footing in research settings, and exposing them to opportunities major governmental agencies can provide. [WATCH TIME: 4 minutes]
In this episode, Greenberg and Bennett provide some perspective on the fluidity of MOGAD diagnosis and how it could potentially change over time as more is understood about neuroimmune disorders. [WATCH TIME: 5 minutes]
In this segment, the duo of neurologists provided a number of informative considerations treating clinicians should take when diagnosing MOGAD, emphasizing careful testing and interpretation of data in this complex process. [WATCH TIME: 4 minutes]
The general neurologist at Brigham and Women’s Hospital described the approach and mindset in teaching neurology as the field continuously evolves. [WATCH TIME: 3 minutes]
The consultant neurologist at Imperial College Healthcare Trust discussed how smoldering MS challenges traditional views of disease progression, seeking combined therapies targeting both inflammatory activity and mechanisms driving smoldering-associated worsening. [WATCH TIME: 4 minutes]
At the 2024 AUPN Annual Meeting, a pair of neurologists provided perspectives on the attributes and ethics that make a great educator, stressing passion, intellectual humility, and inclusivity, among others. [WATCH TIME: 5 minutes]
Neurology News Network. for the week ending September 14, 2024. [WATCH TIME: 4 minutes]
Stuart Isaacson, MD, Rajesh Pahwa, MD, and Jennifer Goldman, MD discuss optimizing PD treatment with levodopa and adjunct therapies, addressing patient and pharmacologic challenges, coordinating care, and anticipating the impact of emerging therapies and upcoming Medicare Part D changes.
The consultant neurologist at Imperial College Healthcare Trust highlighted the importance of acknowledging smoldering multiple sclerosis, urging a shift in therapeutic focus beyond relapses and advocating for a new approach to disease management. [WATCH TIME: 5 minutes]
The disease area stronghold leader in neurodegeneration at Johnson & Johnson provided insight on the importance of the Global Neurodegeneration Proteomics Consortium, illustrated in several presentations at the recently concluded AAIC 2024. [WATCH TIME: 7 minutes]
The consultant neurologist at Imperial College Healthcare Trust talked about how smoldering disease in multiple sclerosis encompasses disease progression independent of relapsing activity, thus broadening the scope beyond traditional measures. [WATCH TIME: 4 minutes]
The global head of neurology development at Sanofi discussed the safety profile of tolebrutinib, an investigational BTK inhibitor, and how treatments like it may help transform the care for patients with multiple sclerosis. [WATCH TIME: 5 minutes]
A group of clinician researchers at NYU Langone provided insight on a study presented at AAIC 2024 looking at the correlations between quantitative gait measures and Alzheimer disease biomarkers. [WATCH TIME: 4 minutes]
The chief executive officer and founder at CureDuchenne discussed efforts to bring specialized physical therapy and infrastructure support to underserved regions to improve care for patients impacted by Duchenne worldwide. [WATCH TIME: 5 minutes]
Neurology News Network. for the week ending September 7, 2024. [WATCH TIME: 4 minutes]
The global head of neurology development at Sanofi provided insight on how tolebrutinib may overcome the challenges of treating non-relapsing secondary progressive multiple sclerosis. [WATCH TIME: 5 minutes]
The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute provided commentary on the future outlook of gene therapies for patients with epilepsy, and some of the knowledge and technical barriers clinicians currently face. [WATCH TIME: 5 minutes]
This discussion examines the 138-week data on ravulizumab for NMOSD, focusing on long-term relapse rates, and share practical tips for effective NMOSD management in clinical settings.
The medical director of the Toronto Memory Program at the University of Toronto provided an in-depth overview of results from an ongoing phase 1 study assessing mivelsiran as a treatment for patients with early-stage Alzheimer disease. [WATCH TIME: 8 minutes]
Neurology News Network. for the week ending August 31, 2024. [WATCH TIME: 4 minutes]
The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute discussed the parameters of an upcoming educational event that highlights the current and future role of sEEG in epilepsy surgery. [WATCH TIME: 5 minutes]
The chairman and chief executive officer at Biomed discussed the additive benefits of combination therapy for Alzheimer disease, providing context on the strengths of different drugs and how it might lead to a more precision medicine approach. [WATCH TIME: 6 minutes]
This discussion examines how disability accumulation may be influenced by the use of less efficacious treatments, compares the efficacy of novel and traditional NMOSD agents in clinical practice, and reviews relapse rates associated with FDA-approved treatments versus off-label and older therapies.
This discussion covers the factors leading to relapses and recurring attacks in NMOSD, how disease severity and relapses contribute to disability accumulation, and their impact on patients' quality of life.
The director of neurology and neuromuscular medicine at the Children’s Hospital of the King’s Daughters in Norfolk, Virginia, discussed SMA Awareness Month and the enhancements to newborn screening for the disease. [WATCH TIME: 4 minutes]
The director of academic clinical research at Orlando Health reflected on the journey of a blood test for traumatic brain injury to clinical use, highlighting the collaborative efforts and patient participation that made it possible. [WATCH TIME: 3 minutes]
The director of academic clinical research at Orlando Health talked about applying Abbott's blood test for suspected mild traumatic brain injury, providing results within 15 minutes, in the clinical practice. [WATCH TIME: 5 minutes]
The postdoctoral researcher at Amsterdam University Medical Center talked about the development of the DAAE score, a tool for predicting the risk of transition to secondary progressive multiple sclerosis. [WATCH TIME: 8 minutes]
The medical director of the Toronto Memory Program at the University of Toronto gave clinical perspective on the promise of mivelsiran, an investigational RNA interference therapeutic, and the idea behind using RNA therapies to treat Alzheimer disease. [WATCH TIME: 5 minutes]
The professor of human genetics at the University of Miami discussed the significance of various genetic factors in Alzheimer risk and highlighted ongoing research, therapeutic challenges as well as the need for global collaboration. [WATCH TIME: 10 minutes]
